Monday, April 24, 1995
Merrill Lynch analyst Jeffrey Casdin raised his 1995 EPS estimate on the Thousand Oaks, Calif., company to $3.75 from $3.70. He noted that Epogen
erythropoietin is continuing its growth spurt and that Neupogen
G-CSF sales are growing rapidly in Europe while slowing in the more mature U.S. market.